AKT1 and melanoma: Mutations in AKT1, AKT3, PIK3CA, PIK3CG, PIK3R2 or PHLPP1, as well as PTEN loss or the overexpression of multiple receptor tyrosine kinases (RTKs), including epidermal growth factor receptors (EGFRs), insulin-like growth factor 1 receptors, platelet-derived growth factor receptors α and β or fibroblast growth factor receptor 3 have been reported in resistant melanoma tumors [28].